BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a research report released on Wednesday morning.
A number of other brokerages have also recently issued reports on PGNX. Cantor Fitzgerald reissued a buy rating and issued a $15.00 target price on shares of Progenics Pharmaceuticals in a research report on Thursday, November 2nd. Zacks Investment Research cut Progenics Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, January 6th. Finally, ValuEngine cut Progenics Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $12.35.
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) traded up $0.17 during midday trading on Wednesday, hitting $5.72. The company had a trading volume of 801,200 shares, compared to its average volume of 1,117,049. The firm has a market cap of $390.00, a PE ratio of -7.35 and a beta of 3.41. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.80. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $11.72.
ILLEGAL ACTIVITY WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/02/15/progenics-pharmaceuticals-pgnx-raised-to-hold-at-bidaskclub.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.